These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39216967)

  • 1. Spesolimab use in generalised pustular psoriasis flares.
    Osborne S; Thacker S; Kam O; Wescott R; Wu JJ
    Lancet; 2024 Aug; 404(10455):846-847. PubMed ID: 39216967
    [No Abstract]   [Full Text] [Related]  

  • 2. Spesolimab use in generalised pustular psoriasis flares - Authors' reply.
    Lebwohl MG; Thoma C; Haeufel T
    Lancet; 2024 Aug; 404(10455):847-848. PubMed ID: 39216969
    [No Abstract]   [Full Text] [Related]  

  • 3. Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval.
    Gwillim EC; Nichols AJ
    Front Immunol; 2024; 15():1359481. PubMed ID: 39104539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of Spesolimab for Generalized Pustular Psoriasis.
    Bachelez H; Choon SE; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Anadkat MJ; Rajeswari S; Hua H; Vulcu SD; Hall D; Tetzlaff K; Thoma C; Lebwohl MG;
    N Engl J Med; 2021 Dec; 385(26):2431-2440. PubMed ID: 34936739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spevigo® (Spesolimab-Sbzo) Injection for the Treatment of Generalized Pustular Psoriasis.
    Gupta AK; Mann A; Vincent K; Abramovits W
    Skinmed; 2024; 22(2):134-137. PubMed ID: 39089999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
    Elewski BE; Lebwohl MG; Anadkat MJ; Barker J; Ghoreschi K; Imafuku S; Mrowietz U; Li L; Quaresma M; Thoma C; Bachelez H
    J Am Acad Dermatol; 2023 Jul; 89(1):36-44. PubMed ID: 36870370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.
    Bukhari T; Markovina M; Abduelmula A; Rankin BD; Vender R; Yeung J; Devani AR; Prajapati VH
    Skin Therapy Lett; 2024 Jan; 29(1):1-4. PubMed ID: 38271532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis.
    Burden AD
    Expert Rev Clin Immunol; 2023 May; 19(5):473-481. PubMed ID: 36960829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
    Morita A; Strober B; Burden AD; Choon SE; Anadkat MJ; Marrakchi S; Tsai TF; Gordon KB; Thaçi D; Zheng M; Hu N; Haeufel T; Thoma C; Lebwohl MG
    Lancet; 2023 Oct; 402(10412):1541-1551. PubMed ID: 37738999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
    Morita A; Tsai TF; Yee EYW; Okubo Y; Imafuku S; Zheng M; Li L; Quaresma M; Thoma C; Choon SE
    J Dermatol; 2023 Feb; 50(2):183-194. PubMed ID: 36282833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spesolimab: A Novel Treatment for Pustular Psoriasis.
    Ratnarajah K; Jfri A; Litvinov IV; Netchiporouk E
    J Cutan Med Surg; 2020; 24(2):199-200. PubMed ID: 32208020
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.
    Mittal S
    Indian J Dermatol Venereol Leprol; 2021; 87(1):119-121. PubMed ID: 33037161
    [No Abstract]   [Full Text] [Related]  

  • 13. Spesolimab: Is it a new treatment target in palmoplantar pustulosis?
    Huang H; Zhang Y; Wu Y; Li C
    Int J Rheum Dis; 2024 May; 27(5):e15154. PubMed ID: 38720596
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.
    Burden AD; Okubo Y; Zheng M; Thaçi D; van de Kerkhof P; Hu N; Quaresma M; Thoma C; Choon SE
    Exp Dermatol; 2023 Aug; 32(8):1279-1283. PubMed ID: 37140190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab.
    Nagata M; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Sugiura K; Tada Y
    J Am Acad Dermatol; 2020 Mar; 82(3):758-761. PubMed ID: 31560979
    [No Abstract]   [Full Text] [Related]  

  • 16. Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab.
    Hlaca N; Zagar T; Kastelan M; Brajac I; Prpic-Massari L
    Clin Exp Dermatol; 2021 Dec; 46(8):1572-1573. PubMed ID: 34028847
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor.
    Gooderham M; Elewski BE; Pariser DM; Sofen H; Mendelsohn AM; Rozzo SJ; Li Q
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e350-e352. PubMed ID: 31033068
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab.
    Yang C; Wang Y; Li R; Tu P; Wang R
    J Dermatolog Treat; 2024 Dec; 35(1):2334791. PubMed ID: 38565205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spesolimab: First Approval.
    Blair HA
    Drugs; 2022 Nov; 82(17):1681-1686. PubMed ID: 36418672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
    Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
    J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.